Evaluation of tau deposition using ¹⁸F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.

ABSTRACT:

Background

The ability of ¹⁸F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer's disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition using ¹⁸F-PI-2620 PET in beta-amyloid positive subjects with a diagnosis of mild cognitive impairment (MCI) or mild AD dementia and characterize it with respect to amyloid deposition, cerebrospinal fluid (CSF) assessment, hippocampal volume, and cognition.

Methods

Subjects with a diagnosis of MCI due to AD or mild AD dementia and a visually amyloid-positive ¹⁸F-florbetaben PET scan (n=74, 76 ± 7 years, 38 females) underwent a baseline ¹⁸F-PI-2620 PET, T1-weighted magnetic resonance imaging (MRI), CSF assessment

SUBMITTER: Bullich S 

PROVIDER: S-EPMC9327167 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature